Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

Inclusion Criteria: * Aged 18 to 55 years inclusive at the time of signing informed consent * Must agree to adhere to the contraception requirements. * Healthy male or non-pregnant, non-lactating female participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead ECG and laboratory safety tests without any clinically significant abnormalities * Body mass index (BMI) of 18.0 to 32.0 kg/m2 as measured at screening * Weight ≥50 kg at screening Inclusion criteria. Exclusion Criteria: * Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. * History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator * Participants with a history of cholecystectomy or gall stones * Participants with chronic or recurrent infection * Participants who have tested positive for tuberculosis * Participants with a history of shingles within the last two months * History of opportunistic infection while not on immunosuppressive therapy * Part 2 only: Participant has a medical condition that may adversely affect taste or smell activity including but not limited to mouth ulcers, significant gum disease, and respiratory and/or sinus infection or cold * Part 2 only: Participant does not agree to the consumption of, or has any known allergies to any of the food vehicles used in this study (applesauce, chocolate pudding, yogurt) * Participants who have received any IMP (Investigational Medicinal Product) in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer * Participants who have previously been administered IMP in this study * Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood * Participants who are taking, or have taken, any prescribed or over-the-counter drug, hormone replacement therapy (HRT) or herbal remedies (other than up to 4 g of paracetamol per day and hormonal contraception) in the 14 days or 5 elimination half-lives, whichever is longer, before first IMP administration (see Section 11.4). Exceptions may apply, as determined by the investigator * Having any vaccination or planned vaccination within 28 days before Day 1. Participants who received live vaccine within 3 months prior to screening and/or who are planning to receive such a vaccine during the study duration. * History of any drug or alcohol abuse in the past 2 years * Regular alcohol consumption in males \>21 units per week and in females \>14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type) * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * Confirmed positive drugs of abuse test result at screening or admission